{
    "clinical_study": {
        "@rank": "18370", 
        "acronym": "ESTHER-1", 
        "arm_group": [
            {
                "arm_group_label": "A", 
                "arm_group_type": "Experimental", 
                "description": "FE 999049"
            }, 
            {
                "arm_group_label": "B", 
                "arm_group_type": "Active Comparator", 
                "description": "Follitropin Alfa (Gonal-F)"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial investigates the effects of FE 999049 compared to Gonal-F."
        }, 
        "brief_title": "Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed Consent Documents signed prior to screening evaluations\n\n          -  In good physical and mental health\n\n          -  Pre-menopausal females between the ages of 18 and 40 years\n\n          -  Infertile women diagnosed with tubal infertility, unexplained infertility,\n             endometriosis stage I/II or with partners diagnosed with male factor infertility,\n             eligible for in vitro fertilisation (IVF) and/or intracytoplasmic sperm injection\n             (ICSI) using fresh or frozen ejaculated sperm from male partner or sperm donor\n\n          -  Infertility for at least one year before randomisation for subjects \u226437 years or for\n             at least 6 months for subjects \u226538 years (not applicable in case of tubal or severe\n             male factor infertility)\n\n          -  The trial cycle will be the subject's first controlled ovarian stimulation cycle for\n             IVF/ICSI\n\n          -  Hysterosalpingography, hysteroscopy, saline infusion sonography, or transvaginal\n             ultrasound documenting a uterus consistent with expected normal function (e.g. no\n             evidence of clinically interfering uterine fibroids defined as submucous or\n             intramural fibroids larger than 3 cm in diameter, no polyps and no congenital\n             structural abnormalities which are associated with a reduced chance of pregnancy)\n             within 1 year prior to randomisation\n\n          -  Transvaginal ultrasound documenting presence and adequate visualisation of both\n             ovaries, without evidence of significant abnormality (e.g. no endometrioma greater\n             than 3 cm or enlarged ovaries which would contraindicate the use of gonadotropins)\n             and normal adnexa (e.g. no hydrosalpinx) within 1 year prior to randomisation. Both\n             ovaries must be accessible for oocyte retrieval.\n\n          -  Early follicular phase (cycle day 2-4) serum levels of FSH between 1 and 15 IU/L\n             (results obtained within 3 months prior to randomisation)\n\n          -  Body mass index (BMI) between 17.5 and 32.0 kg/m2 (both inclusive) at screening\n\n        Exclusion Criteria:\n\n          -  Known endometriosis stage III-IV\n\n          -  One or more follicles \u226510 mm observed on the transvaginal ultrasound prior to\n             randomisation on stimulation day 1\n\n          -  Known history of recurrent miscarriage (defined as three consecutive losses after\n             ultrasound confirmation of pregnancy (excl. ectopic pregnancy) and before week 24 of\n             pregnancy)\n\n          -  Known abnormal karyotype of subject or of her partner/sperm donor, as applicable,\n             depending on source of sperm used for insemination in this trial.\n\n          -  Any known clinically significant systemic disease (e.g. insulin-dependent diabetes)\n\n          -  Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver\n             or kidney) which can compromise participation in the trial with the exception of\n             controlled thyroid function disease\n\n          -  Known tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus\n             which would contraindicate the use of gonadotropins."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01956110", 
            "org_study_id": "000004", 
            "secondary_id": [
                "2013-001669-17", 
                "U1111-1147-6826"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "A", 
                "intervention_name": "FE 999049", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "B", 
                "intervention_name": "Follitropin Alfa (Gonal-F)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Follicle Stimulating Hormone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "UZ Brussel"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto Alegro, Rio Grande Do Sul", 
                        "country": "Brazil"
                    }, 
                    "name": "Fertilitat and PUC-RS"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burnaby", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Pacific Centre for Reproductive Medicine"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia"
                    }, 
                    "name": "Olive Fertility Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario"
                    }, 
                    "name": "Ottawa Fertility Centre"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prague", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Ivf Cube SE"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark"
                    }, 
                    "name": "Rigshospitalet Fertilitetsklinikken"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France"
                    }, 
                    "name": "Department of Endocrine Gynaecology and Reproductive Medicine, H\u00f4pital Jeanne de Flandre"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "Centro Natalit\u00e0 San Raffaele"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Warszawa", 
                        "country": "Poland"
                    }, 
                    "name": "The nOvum Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "IVF & Reproductive Genetics Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "IVI Sevilla"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Glasgow Centre for Reproductive Medicine Ltd."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Brazil", 
                "Canada", 
                "Czech Republic", 
                "Denmark", 
                "France", 
                "Italy", 
                "Poland", 
                "Russian Federation", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme", 
        "overall_contact": {
            "email": "DK0-Disclosure@ferring.com", 
            "last_name": "Clinical Development Support"
        }, 
        "overall_contact_backup": {
            "last_name": "There may be multiple sites for each participating country"
        }, 
        "overall_official": {
            "affiliation": "Ferring Pharmaceuticals", 
            "last_name": "Clinical Development Support", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: Federal Agency for Medicinal Products and Health Products", 
                "Belgium: Ethics Committee", 
                "Brazil: Ethics Committee", 
                "Brazil: National Committee of Ethics in Research", 
                "Brazil: National Health Surveillance Agency", 
                "Canada: Ethics Review Committee", 
                "Canada: Health Canada", 
                "Czech Republic: Ethics Committee", 
                "Czech Republic: State Institute for Drug Control", 
                "Denmark: Ethics Committee", 
                "Denmark: Danish Medicines Agency", 
                "France: Committee for the Protection of Personnes", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Italy: Ethics Committee", 
                "Italy: The Italian Medicines Agency", 
                "Poland: Ethics Committee", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Russia: Ethics Committee", 
                "Russia: Ministry of Health of the Russian Federation", 
                "Spain: Ethics Committee", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Ongoing pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "10-11 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Ongoing implantation rate", 
                "safety_issue": "No", 
                "time_frame": "10-11 weeks after blastocyst transfer"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01956110"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Vital pregnancy rate", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Implantation rate", 
                "safety_issue": "No", 
                "time_frame": "5-6 weeks after blastocyst transfer"
            }, 
            {
                "measure": "Proportion of subjects with extreme ovarian responses, defined as <4, \u226515 or \u226520 oocytes retrieved", 
                "safety_issue": "Yes", 
                "time_frame": "On the day of oocyte retrieval"
            }, 
            {
                "measure": "Proportion of subjects with early OHSS (ovarian hyperstimulation syndrome) and/or preventive interventions for early OHSS", 
                "safety_issue": "Yes", 
                "time_frame": "\u22649 days after triggering of final follicular maturation"
            }, 
            {
                "measure": "Proportion of subjects with cycle cancellation due to poor ovarian response or excessive ovarian response", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Number of oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "Day of oocyte retrieval"
            }, 
            {
                "measure": "Proportion of subjects with <4, 4-7, 8-14, 15-19 and \u226520 oocytes retrieved", 
                "safety_issue": "No", 
                "time_frame": "On the day of oocyte retrieval"
            }, 
            {
                "measure": "Percentage of metaphase II oocytes (for subjects inseminated using ICSI)", 
                "safety_issue": "No", 
                "time_frame": "On the day of oocyte retrieval"
            }, 
            {
                "measure": "Fertilisation rate", 
                "safety_issue": "No", 
                "time_frame": "On day 1 after oocyte retrieval"
            }, 
            {
                "measure": "Quality of embryos", 
                "safety_issue": "No", 
                "time_frame": "On day 3 after oocyte retrieval"
            }, 
            {
                "measure": "Quality of blastocysts", 
                "safety_issue": "No", 
                "time_frame": "On day 5 after oocyte retrieval"
            }, 
            {
                "measure": "Total gonadotropin dose", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Number of stimulation days", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Proportion of subjects with investigator-requested gonadotropin dose adjustments", 
                "safety_issue": "No", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Frequency of injection site reactions (redness, pain, itching, swelling and bruising) assessed by the subject during the stimulation period", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 stimulation days"
            }, 
            {
                "measure": "Abdominal discomfort related to controlled ovarian stimulation as assessed by a visual analogue scale", 
                "safety_issue": "Yes", 
                "time_frame": "By end of the stimulation and the day of blastocyst transfer"
            }, 
            {
                "measure": "Changes in body weight", 
                "safety_issue": "No", 
                "time_frame": "From day 1 to the end of the stimulation period and the day of blastocyst transfer"
            }, 
            {
                "measure": "Changes in maximum abdominal circumference", 
                "safety_issue": "No", 
                "time_frame": "From day 1 to the end of the stimulation period and the day of blastocyst transfer"
            }, 
            {
                "measure": "Proportion of subjects with treatment-induced anti-FSH antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days after end of the stimulation period"
            }, 
            {
                "measure": "Proportion of subjects with late OHSS", 
                "safety_issue": "Yes", 
                "time_frame": ">9 days after triggering of final follicular maturation"
            }, 
            {
                "measure": "Technical malfunctions of the administration pen", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 20 stimulation days"
            }
        ], 
        "source": "Ferring Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ferring Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}